Posted by Michael Wonder on 24 Feb 2023
FDA approves once weekly Altuviiio, a new class of factor VIII therapy for haemophilia A that offers significant bleed protection
23 February 2023 - FDA approves once weekly Altuviiio, a new class of factor VIII therapy for haemophilia A that offers significant bleed protection.
The US FDA has approved Altuviiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl], previously referred to as efanesoctocog alfa, a first in class, high sustained factor VIII replacement therapy.
